Wide Ranks

MYGN

Myriad Genetics, Inc.

16.28

Top Statistics
Market Cap 1 B Forward PE 119.33 Revenue Growth 11.20 %
Current Ratio 1.90 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -14.09 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -44.99 Enterprise / Revenue 1.85 Price To Sales Trailing12 Months 1.80
Profitability
Profit Margins -14.09 % Operating Margins -8.35 %
Balance Sheet
Total Cash 99 M Total Cash Per Share 1.10 Total Debt 143 M
Total Debt To Equity 19.56 Current Ratio 1.90 Book Value Per Share 8.04
All Measures
Short Ratio 396.00 % Message Board Id finmb_31822 Fax 801 584 3640
Shares Short Prior Month 4 M Return On Equity -0.1640 City Salt Lake City
Uuid a15ca704-b4ab-351f-8b50-c0bf16b137c5 Previous Close 16.17 First Trade Date Epoch Utc 812 M
Book Value 8.04 Beta 1.94 Total Debt 143 M
Volume 681909 Price To Book 2.02 Last Split Date 1 B
Fifty Two Week Low 14.72 Total Cash Per Share 1.10 Total Revenue 823 M
Shares Short Previous Month Date 1 B Target Median Price 24.00 Max Age 86400
Recommendation Mean 2.50 Sand P52 Week Change 0.3133 Operating Margins -8.35 %
Last Dividend Value 1.75 Target Mean Price 23.79 Net Income To Common -116000000
Short Percent Of Float 0.0568 Implied Shares Outstanding 91 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 973490 Average Volume10days 973490
Total Cash 99 M Next Fiscal Year End 1 B Revenue Per Share 9.21
Held Percent Insiders 0.0202 Ebitda Margins -4.12 % Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 16.17
Target Low Price 15.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 21.52
Open 16.33 Free Cashflow -52900000 State UT
Dividend Yield 0.00 % Return On Assets -0.0535 Time Zone Short Name EST
Trailing Eps -1.28 Day Low 16.07 Address1 322 North 2200 West
Shares Outstanding 91 M Price Hint 2 Target High Price 35.00
Website https://www.myriad.com 52 Week Change -0.1472 Average Volume 821168
Forward Eps 0.1500 Recommendation Key buy Compensation As Of Epoch Date 1 B
Quick Ratio 146.20 % Last Split Factor 2:1 Regular Market Day High 16.53
Is_sp_500 False Profit Margins -14.09 % Debt To Equity 19.56
Fifty Two Week High 29.30 Day High 16.53 Shares Short 3 M
Regular Market Open 16.33 Industry Key diagnostics-research Earnings Growth 0.00 %
Enterprise To Revenue 1.85 Revenue Growth 11.20 % Shares Percent Shares Out 0.0406
Operating Cashflow -70000000 Currency USD Time Zone Full Name America/New_York
Market Cap 1 B Is_nasdaq_100 False Zip 84116
Quote Type EQUITY Industry Diagnostics & Research Long Name Myriad Genetics, Inc.
Regular Market Day Low 16.07 Held Percent Institutions 1.02 Current Price 16.28
Enterprise To Ebitda -44.99 Financial Currency USD Current Ratio 1.90
Gross Margins 69.15 % Industry Disp Diagnostics & Research Number Of Analyst Opinions 14
Country United States Float Shares 83 M Two Hundred Day Average 23.33
Ir Website http://investor.myriad.com/ Enterprise Value 1 B Price To Sales Trailing12 Months 1.80
Forward PE 119.33 Regular Market Volume 681909 Last Dividend Date 1 B
Ebitda -33900000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally.

It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics.

It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer.

It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus.

It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions.

It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer.

The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.